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Abstract
Introduction and hypothesis The objective of this study was
to assess outcomes following robotic sacrocolpopexy using a
lightweight polypropylene Y-mesh.
Methods During our study period, all patients who underwent
robotic sacrocolpopexy were enrolled in this single-arm pro-
spective trial. Endpoints included Pelvic Organ Prolapse
Quantification (POP-Q) values; Pelvic Floor Distress Inven-
tory, short form 20 (PFDI-20); Pelvic Floor Impact Question-
naire, short form 7 (PFIQ-7); Surgical Satisfaction scores; and
the Sandvik Incontinence Severity Index. All surgeries were
performed with a pre-configured monofilament type 1 poly-
propylene Y-mesh (Alyte©, C.R. Bard, Covington, GA,
USA). Cure rates at 12 months were calculated using two
separate definitions: (1) “clinical cure”: no POP-Q points>0,
point C ≤ −5, no prolapse symptoms on the PFDI-20, and no
reoperations for prolapse and (2) “objective anatomic cure”:
POP-Q stage 0 or 1, point C of ≤ −5, and no reoperations for
prolapse.
Results A total of 150 patients underwent robotic
sacrocolpopexy and 143 (95 %) were available for 12-month
follow-up. Mean age was 58.6 ± 9.8 and mean body mass
index was 26.3 ± 4.5. Mean operative time and blood loss
were 148±27.6 min (range 75–250 min) and 51.2±32, re-
spectively. There were no mesh erosions or exposures, and
mesh edges were not palpable in any patient. At 12months the
clinical cure rate was 95 %, and the objective anatomic cure
rate was 84 %. The PFDI-20 mean score improved from 98 at
baseline to 17 at 12 months (p <0.0001); PFIQ-7 scores
improved from 59 to 6.5 (p <0.0001).
Conclusions Robotic sacrocolpopexy using this lightweight
polypropylene Y-mesh offers excellent subjective and objec-
tive results at 1 year.
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Introduction
Over the past 50 years, the sacrocolpopexy procedure has
gone through quite an evolution. Originally an open abdom-
inal procedure designed primarily for the correction of recur-
rent vaginal vault prolapse, the sacrocolpopexy is now often
performed via the laparoscopic approach—with or without
robotic assistance—for virtually any variety of pelvic organ
prolapse (POP) whether or not the patient has a uterus [1]. It’s
not only the route and scope of the procedure that have
evolved—the graft materials used for the procedure have
changed over time as well. A 2004 comprehensive review of
sacrocolpopexy by Nygaard et al. essentially established the
procedure as the de facto “gold standard” for POP [2]. In that
report, over 80 % of the surgical cases referenced had been
performed with one relatively heavy polypropylene mesh
(Marlex, C.R. Bard, Covington, GA, USA). That particular
mesh product has a density of 95 g/m2, which may partially
explain the significant rates of mesh-related complications
such as erosion (3.4 %), pain (2.7 %), and dyspareunia
(8.7 %) contained in Nygaard et al.’s review. Recently, in an
attempt to minimize mesh-related complications, medical de-
vice companies have developed much lighter-weight polypro-
pylene mesh products with densities of less than 20 g/m2. All
of these products received US Food and Drug Administration
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(FDA) approval for sacrocolpopexy via the 510(k) process,
which means that no clinical research was required prior to
release of these new lightweight meshes.While these products
should result in fewer mesh-related complications, they beg
the question “how light is too light?” In other words, will there
be efficacy trade-offs when these lightweight mesh products
are used for sacrocolpopexy? Obviously, each new light-
weight mesh product should be scrutinized via prospective
clinical trials in order to properly answer these efficacy ques-
tions. To that end our objective was to prospectively evaluate
objective and subjective results at least 1 year after robotic-
assisted laparoscopic sacrocolpopexy using a new lightweight
Y-shaped polypropylene mesh material.
Materials and methods
This single-arm prospective studywas approved by theAtlantic
Health System Institutional Review Board (R10-06-005) and
was listed on the site www.clinicaltrials.gov (#NCT01320644).
The inclusion criteria included patients who had been through
our standard informed consent process and chosen to undergo
robotic-assisted laparoscopic sacrocolpopexy. Exclusion
criteria included enrollment in any other research study or
desire to undergo sacrocolpopexy using a different graft mate-
rial. All patients who underwent robotic-assisted laparoscopic
sacrocolpopexy during our study period were enrolled in this
trial. Participants’ demographic information was recorded in-
cluding age, body mass index (BMI), ethnicity, history of prior
prolapse or incontinence surgery and/or prior hysterectomy,
smoking, and menopausal status. Due to our desire to perform
supracervical rather than total hysterectomies (and thus
morcellate the specimens), we maintained a low threshold of
suspicion for uterine pathology. Any history suggestive of
postmenopausal bleeding prompted us to perform an endome-
trial biopsy.
All surgeries were performed at Morristown Medical Cen-
ter or Overlook Medical Center, which are community-based
tertiary care teaching hospitals in northern New Jersey. Peri-
operative data were collected including concomitant opera-
tions, operative time, estimated blood loss, length of hospital
stay, hospital readmissions, blood transfusions, and conver-
sions to laparotomy. Any intraoperative or postoperative ad-
verse events were recorded as well. All surgeries were per-
formed via our previously reported standardized techniques
[1, 11]. For each operation, the surgical team consisted of one
attending surgeon and one urogynecology fellow. Briefly, the
polypropylene Y-shaped mesh (Alyte® Y-mesh graft, C.R.
Bard, Covington, GA, USA) was tailored to each patient’s
defect such that it could be fastened down the anterior vaginal
wall to the area adjacent to the trigone and down the posterior
vaginal wall to the perineum. The mesh was fastened to the
vagina using interrupted polytetrafluoroethylene sutures (CV4
Gore-Tex suture on TH-26 needles, Gore Medical Products
Division, Flagstaff, AZ, USA). The proximal graft attach-
ments to the anterior longitudinal ligament were performed
via zero-gauge polyester sutures (Ethibond on SH needles,
Ethicon, Somerville, NJ, USA), and the mesh was covered
with peritoneum using zero-gauge poliglecaprone sutures
(Monocryl on CT-1 needles, Ethicon, Somerville, NJ, USA).
Operative time was defined as the time from incision to
closure of the trocar sites. Concomitant suburethral slings
were offered to patients who demonstrated stress incontinence
with reduction of their prolapse on urodynamic studies.
In an effort to send our patients home without Foley cath-
eter drainage, we employed a nonconventional voiding trial
protocol. All Foleys were removed early in the morning of
postoperative day 1, and the nurses were instructed to call the
surgeon to report each voided volume. After each void, the
surgeon would decide whether the given patient could be
discharged home or needed to void again. If another void
was called for, the nurse would call that value to the surgeon
who would again decide whether the patient could be
discharged home. In each case, the surgeon considered the
particular patient’s preoperative voiding function, the voided
amount, and the time interval since catheter removal or since
the last void. This process was repeated for each patient until
the surgeon either discharged her without a Foley catheter
(because he/she believed the patient would continue to void
well) or sent her home with a Foley for subsequent voiding
trial in the office. In an effort to simplify the postoperative
nursing duties, no post-void residual volumes were collected
during this process. For patients who did require indwelling
catheter placement at discharge, we recorded their days to
spontaneous voiding.
Our clinical research nurse collected all outcome measures
at the preoperative, 6-month and 12-month postoperative time
intervals. Objective anatomic measurement of POP was per-
formed via the Pelvic Organ Prolapse Quantification (POP-Q)
system [3]. Subjective assessment of pelvic floor symptoms,
sexual function, urinary incontinence severity, and surgical
satisfaction were recorded via the Pelvic Floor Distress Inven-
tory, short form (PFDI-20), the Pelvic Floor Impact Question-
naire, short form (PFIQ-7), the Pelvic Organ Prolapse/Urinary
Incontinence Sexual Questionnaire (PISQ-12), the Sandvik
Severity Index, and the Surgical Satisfaction Questionnaire
(SSQ-8) [4–7]. During each postoperative vaginal exam, our
clinical research nurse attempted to feel the mesh through the
vaginal epithelium, and her findings were recorded as a yes/no
dichotomous variable depending onwhether she could discern
the mesh edges. She also looked for evidence of mesh expo-
sure at each postoperative visit.
Our primary outcomemeasure was “clinical cure” at 1 year.
To meet our definition of clinical cure, all of the following
were required: (1) no reoperation for POP since the index
surgery, (2) no symptoms of vaginal bulge as measured by
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the PFDI-20, (3) no POP-Q points>0, (4) POP-Q point C≤
−5, and (5) an answer of “satisfied” or “very satisfied” on the
SSQ-8. Unless all five criteria were met, a given patient was
deemed a “clinical failure.” We also recorded a strictly POP-
Q-based definition of cure we called “objective anatomic
cure.” To meet that definition of cure, a patient had to have
POP-Q point C≤ −5, overall POP-Q stage of 0 or 1, and no
reoperation for POP.
As secondary endpoints we recorded scores for the PFDI-
20, PFIQ-7, Sandvik Severity Index, de novo dyspareunia
rates, and SSQ-8. We used question 5 of the 12-month
PISQ-12 data to define de novo dyspareunia among the study
participants who were sexually active both before and after
surgery. Question 5 asks “Do you feel pain during sexual
intercourse?” We defined dyspareunia as an answer of≥2
(“sometimes”).
Statistical analyses were performed using SAS 9.2
(SAS, Cary, NC, USA). The primary outcome was
analyzed using Wilcoxon signed rank test and paired t
test. Additionally, chi-square and Fisher’s exact test
were used with the alpha set to 0.05.
Results
Between August 2010 and May 2011, 150 patients underwent
robotic-assisted laparoscopic sacrocolpopexy at our center
using a lightweight monofilament polypropylene Y-shaped
mesh (Alyte® Y-mesh graft, C.R. Bard, Covington, GA,
USA). All eligible patients were enrolled, and no patients were
excluded by criteria. Of these, 143 patients (95.3 %) returned
for objective and subjective outcome assessment at≥12months;
the remaining 7 patients (4.7 %) were lost to follow-up after
their first postoperative visit. Table 1 lists preoperative charac-
teristics of our study group. All patients who presented with an
intact uterus received a supracervical hysterectomy as the first
step of their sacrocolpopexy. Final pathology reports on the
morcellated specimens revealed no unanticipated uterine pa-
thology. Concomitant suburethral slings were placed in 122
(81.3 %) patients. Concomitant perineorrhaphies were per-
formed in 17 (11.3 %) patients. These perineorrhaphies in-
volved plication of the transverse perineal and distal
bulbocavernosus muscles only. In other words, they did not
include any posterior colporrhaphy stitches. Besides these
perineorrhaphies, no other vaginal POP repairs were per-
formed. There were no visceral injuries, blood transfusions,
conversions to laparotomy, or readmissions to the hospital,
and all patients were discharged home on postoperative day
1. The mean blood loss was 51.2±32 ml, and the mean oper-
ative time was 148±27.6 min (range 75–250 min). Only 2 %
(3/150) of patients required indwelling Foley catheter
placement at discharge, and each of these patients void-
ed spontaneously without surgical intervention within
the first postoperative week.
The clinical cure rate was 95 % (136/143). Two patients
developed recurrent symptomatic anterior wall POP beyond the
hymen, and two had recurrent symptomatic posterior wall POP
beyond the hymen. The remaining three clinical failures included
one patient whose POP-Q point C came to -4 (although she had
no POP symptoms and reported being very satisfied with her
surgery) and two patients whose POP-Q values were all at stage
0 or 1 but they reported persistent POP symptoms on PFDI-20.
The objective anatomic cure rate was 84% (120/143). Of the
23 objective anatomic failures, 15 were in the anterior compart-
ment, 7 in the posterior compartment, and 1 at the apex.
Figures 1, 2, and 3 show the mean POP-Q points Ba, Bp, and
C over the study period. Table 2 includes pre- and postoperative
comparisons for our secondary outcome measures.
On the SSQ-8, 96.6 % of patients reported that they were
either very satisfied or satisfied and 96.4 % stated that they










Current smokera 4 (6/150)
Preoperative systemic HRTa 3 (5/150)
Prior hysterectomya 22 (33/150)
Prior prolapse surgerya 11 (16/150)
Prior continence surgerya 9 (13/150)
Caucasiana 97 (145/150)
African Americana 0.67 (1/150)
Asiana 3 (4/150)
Data presented as mean±standard deviation unless otherwise indicated
HRT hormone replacement therapy
a Proportion, % (n /n)
Fig. 1 Point Ba over time
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would recommend the operation to a friend. Sixty-four pa-
tients were sexually active without dyspareunia prior to sur-
gery. Of these, three patients (4.7 %) reported de novo
dyspareunia at 12 months. None of these patients had under-
gone a perineorrhaphy. Given the small number of patients
with this outcome, statistical analyses looking for de novo
dyspareunia risk factors were not feasible.
Discussion
Our results indicated that use of the lightweight Alyte®
Y-mesh for robotic-assisted laparoscopic sacrocolpopexy
resulted in excellent anatomic and functional outcomes.
These results were similar to historical results of the
open abdominal and conventional laparoscopic ap-
proaches for the same operation [8–10] and were essen-
tially identical to our recently published results for
robotic sacrocolpopexies performed with other materials
[1, 11]. Had we decided to count our seven patients
who were lost to follow-up as failures, our clinical cure
rate and objective anatomic cure rate would have been
91 and 80 %, respectively. The mean improvements in
PFDI-20 and PFIQ-7 scores were well above the mini-
mum clinically important difference (MCID) threshold
reported by Barber et al. [4]. Furthermore, we achieved
these cure rates in the face of no complications and
minimal morbidity.
Our high rate of concomitant suburethral sling placement
reflects our practice of offering this procedure to patients
demonstrating stress incontinence during urodynamics while
their prolapse is reduced. In our practice, the majority of such
patients choose sling placement concomitant to their prolapse
repair. All of these slings were the “bottom-up” retropubic
type (Align®, C.R. Bard, Covington, GA, USA).
One of our most compelling findings was the lack of mesh-
related complications during the first postoperative year. The
absence of mesh exposure or erosion was probably a function
of both the lightweight mesh used and the significant number
of patients for which we performed a supracervical hysterec-
tomy as the first surgical step. Furthermore, our clinical re-
search nurse was not able to palpate the mesh through the
vaginal epithelium in any patient. We attribute the absence of
vaginal suture erosion or granulation tissue to our efforts to
avoid full-thickness vaginal bites when securing the mesh, as
we do not routinely ask patients to use postoperative vaginal
estrogen.
It is also important to note that our simplified ap-
proach to establishing postoperative voiding status was
well received by patients and nurses alike. By simply
asking the nurses to report each voided volume for each
patient we were able to eliminate the anxiety that often
surrounded our previous voiding trial protocols (such as
backfilling the bladder or checking post-void residuals).
We were able to discharge 98 % of our patients home
without indwelling catheters, and none of these patients
required sling revisions or experienced voiding dysfunc-
tion thereafter.
Fig. 2 Point Bp over time
Fig. 3 Point C over time
Table 2 Pre- and postoperative data for the group of patients who
completed≥12 months follow-up (n =143)
Pre-op 12 months post-op p
Point C 0.5±4 −8±2 <0.01
Point Ba 2.5±4 −2.5±2 <0.01
Point Bp −0.7±2 −2.5±1 <0.01
TVL 9.4±1 9.5±1 1.0
GH 3.5±2 2.6±2 0.09
PB 2.5±1 2.7±1 0.7
PFDI-20 98±19 17±8 <0.01
PFIQ-7 58±17 6.5±5 <0.01
PISQ-12a 33±9 42±6 <0.01
SSI 2.3±1 1.3±1 <0.01
Data presented as mean±standard deviation unless otherwise indicated
TVL total vaginal length, GH genital hiatus, PB perineal body, PFDI-20
Pelvic Floor Distress Inventory, short form 20 [4], PFIQ-7 Pelvic Floor
Impact Questionnaire, short form 7 [4], PISQ-12 Pelvic Organ Prolapse/
Urinary Incontinence Sexual Questionnaire 12 [5], SSI Sandvik Severity
Index (urinary incontinence) [8]
a Calculated for patients who reported pre- and postoperative sexual
activity (n=97)
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The strengths of our study included the prospective design,
the standardization of the surgical techniques, and the fact that
all outcome measures were obtained by our clinical research
nurse. Our lack of a randomization, lack of blinding (of either
the clinical research nurse or the patients), and lack of a
control group were our main weaknesses. Also, our choice
of 12-month follow-up (rather than 3 or 5 years) could be
thought of as a limitation despite the fact that the majority of
POP recurrences after sacrocolpopexy happen during the first
postoperative year [9]. Another important limitation of our
study was the fact that our results may not be generalizable,
because we used our specific standardized techniques and
were through the robotic learning curve at the study outset.
Nevertheless, as new products enter the marketplace via the
FDA 510(k) process, studies like this one represent important
steps in establishing the efficacy of these newmaterials.While
the added expenses associated with use of the da Vinci robot
may or may not prove to be justified, our 1-year outcomes are
compelling at the very least. We intend to follow this group of
patients over time to determine whether our early success will
prove to be long lasting.
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